| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
With an IC50 of 6.60 μM, schisandrin A (Sch A) potently inhibits the microsomal midazolam 1-hydroxylation process mediated by CYP3A. The dilution assay graph displays the recovery of enzyme activity in the presence and absence of Schisandrin A. Using the Dixon plot, the Ki value of Schisandrin A was found to be 5.83 μM. The research discovered that Schisandrin A deactivated the midazolam 1-hydroxylation activity of rat liver microsomes in a concentration- and time-dependent manner when NADPH was present. Schisandrin A's kappa and Ki are calculated to be 4.51 μM and 0.134/min, respectively [1].
|
|---|---|
| ln Vivo |
In a concentration-dependent manner, schisandrin A (SchA) markedly reduced the CYP3A activity of rat liver microsomes as well as the Vmax value of every group. Schisandrin A suppresses CYP3A activity, as seen by the double reciprocal plot and the quadratic plot, with an apparent Ki value of 30.67 mg/kg. When compared to the Negative group, Schisandrin A also dramatically decreased the plasma concentrations of 1-hydroxymidazolam in each Schisandrin A treatment group, bringing them down to levels comparable to those in the Positive group [2].
|
| References | |
| Additional Infomation |
Schizandrin A is a tannin.
Schizandrin A has been reported in Schisandra bicolor, Schisandra sphenanthera, and other organisms with data available. See also: Schisandra chinensis fruit (part of); Deoxyschizandrin (annotation moved to). |
| Molecular Formula |
C24H32O6
|
|---|---|
| Molecular Weight |
416.514
|
| Exact Mass |
416.219
|
| CAS # |
61281-38-7
|
| Related CAS # |
Schisandrin;7432-28-2
|
| PubChem CID |
155256
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
544.2±50.0 °C at 760 mmHg
|
| Melting Point |
114 °C
|
| Flash Point |
215.6±30.0 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.520
|
| LogP |
5.87
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
30
|
| Complexity |
484
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O(C([H])([H])[H])C1C(=C(C([H])=C2C=1C1=C(C(=C(C([H])=C1C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C2([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H]
|
| InChi Key |
JEJFTTRHGBKKEI-OKILXGFUSA-N
|
| InChi Code |
InChI=1S/C24H32O6/c1-13-9-15-11-17(25-3)21(27-5)23(29-7)19(15)20-16(10-14(13)2)12-18(26-4)22(28-6)24(20)30-8/h11-14H,9-10H2,1-8H3/t13-,14+
|
| Chemical Name |
(9S,10R)-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaene
|
| Synonyms |
Deoxyschizandrin Schizandrin A Deoxyschisandrin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~120.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (6.00 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4009 mL | 12.0045 mL | 24.0090 mL | |
| 5 mM | 0.4802 mL | 2.4009 mL | 4.8018 mL | |
| 10 mM | 0.2401 mL | 1.2005 mL | 2.4009 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03402308 | COMPLETED | Dietary Supplement: Schisandra chinensis extract Dietary Supplement: Placebo |
Muscular Sarcoidosis | Pusan National University Yangsan Hospital | 2017-06-01 | Not Applicable |
| NCT01472822 | COMPLETEDWITH RESULTS | Dietary Supplement: Omija extract. Dietary Supplement: Placebo |
Mild Knee Osteoarthritis | Chonbuk National University Hospital | 2011-03 | Phase 2 Phase 3 |
| NCT04598243 | UNKNOWN STATUS | Dietary Supplement: Smart Energy System | CFS Fibromyalgia |
Practitioners Alliance Network | 2020-10-14 | Early Phase 1 |
| NCT01068067 | UNKNOWN STATUS | Other: drug (tacrolimus and SchE) and genetics
Drug: tacrolimus |
Renal Transplantation | Sun Yat-sen University | 2010-03 | Not Applicable |
| NCT06214195 | RECRUITING | Drug: Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis) |
Cardiotoxicity Induced by Drug Therapy for Breast Cancer |
Zhejiang Cancer Hospital | 2024-01-20 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
